Efficacy comparison between gastrectomy combined with chemotherapy and chemotherapy alone for treatment of advanced gastric cancer with abdominal para-aortic lymph node metastasis

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-11-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.11.009

Xue Wang, Jiqing Wang, Song Liu

{"title":"Efficacy comparison between gastrectomy combined with chemotherapy and chemotherapy alone for treatment of advanced gastric cancer with abdominal para-aortic lymph node metastasis","authors":"Xue Wang, Jiqing Wang, Song Liu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.11.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the therapeutic effect and prognosis of gastrectomy combined with chemotherapy and chemotherapy alone for treatment of advanced gastric cancer with abdominal para-aortic (the 16th) lymph node metastasis. \n \n \nMethods \nThe clinical data of 236 patients with advanced gastric cancer with abdominal para-aortic (the 16th) lymph node metastasis in Jincheng People's Hospital of Shanxi Province from January 2003 to December 2012 were retrospectively analyzed. According to the treatment method, the patients were divided into chemotherapy alone group (121 cases) and gastrectomy + chemotherapy group (115 cases), and mFOLFOX6 regimen was used for chemotherapy. The efficacy and adverse reactions of the two groups were compared. \n \n \nResults \nThe incidence of upper gastrointestinal adverse events in the gastrectomy+chemotherapy group was higher than that in the chemotherapy alone group [8.7% (10/115) vs. 1.7% (2/121)], and the difference between the two groups was statistically significant (χ 2 = 3.881, P = 0.049). The median overall survival was 14.8 months (10.9-17.8 months) in the chemotherapy alone group and 11.7 months (9.8-15.6 months) in the gastrectomy+chemotherapy group, and there was no significant difference between the two groups (P > 0.05). The 2-year overall survival rate was 32.3% in the chemotherapy alone group and 24.3% in the gastrectomy+chemotherapy group, and there was no significant difference between the two groups (χ 2 = 3.105, P = 0.078). The 2-year progression-free survival rate was 16.5% in the chemotherapy alone group and 20.0% in the gastrectomy+chemotherapy group, and the difference between the two groups was statistically significant (χ 2 = 3.917, P = 0.047). \n \n \nConclusion \nCompared with chemotherapy alone, advanced gastric cancer patients with abdominal para-aortic (the 16th) lymph node metastasis could not benefit from gastrectomy combined with chemotherapy. \n \n \nKey words: \nStomach neoplasms; Drug therapy, combination; Gastrectomy","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"760-763"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.11.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the therapeutic effect and prognosis of gastrectomy combined with chemotherapy and chemotherapy alone for treatment of advanced gastric cancer with abdominal para-aortic (the 16th) lymph node metastasis. Methods The clinical data of 236 patients with advanced gastric cancer with abdominal para-aortic (the 16th) lymph node metastasis in Jincheng People's Hospital of Shanxi Province from January 2003 to December 2012 were retrospectively analyzed. According to the treatment method, the patients were divided into chemotherapy alone group (121 cases) and gastrectomy + chemotherapy group (115 cases), and mFOLFOX6 regimen was used for chemotherapy. The efficacy and adverse reactions of the two groups were compared. Results The incidence of upper gastrointestinal adverse events in the gastrectomy+chemotherapy group was higher than that in the chemotherapy alone group [8.7% (10/115) vs. 1.7% (2/121)], and the difference between the two groups was statistically significant (χ 2 = 3.881, P = 0.049). The median overall survival was 14.8 months (10.9-17.8 months) in the chemotherapy alone group and 11.7 months (9.8-15.6 months) in the gastrectomy+chemotherapy group, and there was no significant difference between the two groups (P > 0.05). The 2-year overall survival rate was 32.3% in the chemotherapy alone group and 24.3% in the gastrectomy+chemotherapy group, and there was no significant difference between the two groups (χ 2 = 3.105, P = 0.078). The 2-year progression-free survival rate was 16.5% in the chemotherapy alone group and 20.0% in the gastrectomy+chemotherapy group, and the difference between the two groups was statistically significant (χ 2 = 3.917, P = 0.047). Conclusion Compared with chemotherapy alone, advanced gastric cancer patients with abdominal para-aortic (the 16th) lymph node metastasis could not benefit from gastrectomy combined with chemotherapy. Key words: Stomach neoplasms; Drug therapy, combination; Gastrectomy

查看原文本刊更多论文

胃切除术联合化疗与单纯化疗治疗晚期癌症腹主动脉旁淋巴结转移的疗效比较

目的探讨胃切除术联合化疗及单纯化疗治疗晚期癌症腹主动脉旁（第16）淋巴结转移的疗效及预后。方法回顾性分析2003年1月至2012年12月山西省晋城市人民医院收治的236例晚期癌症腹主动脉旁（第16）淋巴结转移患者的临床资料。根据治疗方法，将患者分为单纯化疗组（121例）和胃切除术+化疗组（115例），采用mFOLFOX6方案进行化疗。比较两组的疗效及不良反应。结果胃癌+化疗组上消化道不良事件发生率高于单纯化疗组[8.7%（10/115）vs.1.7%（2/121）]，两组比较差异有统计学意义（χ，2年总生存率单纯化疗组为32.3%，胃切除术+化疗组为24.3%，两组比较无显著性差异（χ2=3.105，P=0.078）。单纯化疗组2年无进展生存率为16.5%，胃切除术+化疗组为20.0%，两组比较有统计学意义（χ2=3.917，P=0.047），晚期癌症合并腹主动脉旁（第16位）淋巴结转移者，胃切除术联合化疗无效。关键词：胃肿瘤；药物治疗，联合用药；胃切除术

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.